Circle Of Life: Raptor Buys Quinsair After Its Return To Original Developer
This article was originally published in Scrip
Quinsair (inhaled levofloxacin) – originally known as Aeroquin – took a circuitous route to its new home at Raptor Pharmaceuticals, which will pay Tripex Pharmaceuticals $68.4m up front and up to $350m in milestone fees plus a small royalty for the cystic fibrosis (CF) drug.
You may also be interested in...
Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.
Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.
Dozens of health care-focused special purpose acquisition corporations have gone public during the past two years but many biopharma firms that have merged with SPACs have not performed well to date, raising the question of how long the SPAC boom will last.